Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$68.16
+0.9%
$72.70
$29.42
$117.33
$7.16B0.151.18 million shs1.10 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.36
+1.5%
$1.32
$1.21
$2.04
$1.06B1.343.88 million shs1.61 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.63
+8.9%
$3.55
$2.28
$6.71
$539.13M1.71.16 million shs1.15 million shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
$53.01
$53.01
$25.02
$65.00
$2.91B0.431.07 million shsN/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
+0.92%-1.66%-2.07%-6.59%+130.97%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.49%+2.26%0.00%-8.72%+5.43%
Organogenesis stock logo
ORGO
Organogenesis
+8.94%+22.49%+52.81%+13.48%+64.77%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%0.00%
Viela Bio, Inc. stock logo
VIE
Viela Bio
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.6842 of 5 stars
3.51.00.04.32.74.21.9
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.5361 of 5 stars
3.42.00.04.42.25.00.6
Organogenesis stock logo
ORGO
Organogenesis
4.3376 of 5 stars
3.03.00.04.31.94.20.6
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.25102.83% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75102.21% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0029.59% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TARO, OPK, CORT, VIE, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$675.04M10.71$1.25 per share54.38$6.49 per share10.50
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.51$0.07 per share19.48$2.00 per share0.68
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.22$0.23 per share20.37$2.09 per share2.22
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
Viela Bio, Inc. stock logo
VIE
Viela Bio
$50M58.26N/AN/A$7.14 per share7.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$141.21M$1.1658.7636.84N/A19.33%20.40%16.64%8/4/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/A

Latest TARO, OPK, CORT, VIE, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
8/4/2025Q2 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.23N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.07
2.96
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/A
19.51
19.49

Institutional Ownership

CompanyInstitutional Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
91.40%
Viela Bio, Inc. stock logo
VIE
Viela Bio
46.98%

Insider Ownership

CompanyInsider Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.50%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
13.80%
Viela Bio, Inc. stock logo
VIE
Viela Bio
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.04 million84.31 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable
Viela Bio, Inc. stock logo
VIE
Viela Bio
16654.95 millionN/ANot Optionable

Recent News About These Companies

BETDAQ app download
dc vs punjab 2022
Khelo India Khelo lucky 3 result today
777 Win Sooter
RGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-Dollar
Roche takes on Alexion as FDA approves satralizumab in NMOSD
Regenxbio Names Mitchell Chan CFO
2024 Fire Awards: Meet this year's Ablaze honorees

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$68.16 +0.62 (+0.92%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$69.00 +0.84 (+1.23%)
As of 07/8/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.36 +0.02 (+1.49%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.36 +0.00 (+0.37%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.63 +0.38 (+8.94%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$4.76 +0.13 (+2.81%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Viela Bio stock logo

Viela Bio NASDAQ:VIE

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.